Preclinical development of combination therapy targeting the dominant cytokine interleukin-1β for renal cell carcinoma.

e14237Background: Targeting myeloid-derived suppressor cells (MDSCs), key mediators of intrinsic and adaptive immune resistance, remains a significant challenge in kidney cancer immunotherapy. One ...